Cipla Limited (CIPLA) — Board Meeting

📢 Key Event
Shareholders approved financial statements and reappointed Adil Zainulbhai as director.

🔄 What Changed
Revenue reached ₹28,000+ crores with 21% EBITDA margin; dividend declared at ₹13 per share.

🔮 What's Next
40-50 new US/EU product filings over three years; Tirzepatide partnership advancing; hybrid AGM to be considered.

💡 Investor Takeaway
Cipla is prioritizing high-margin complex products and global expansion while maintaining shareholder returns.

Cipla held its 90th AGM on 25 June 2026, highlighting ₹28,000+ crores revenue, 21% EBITDA margin, and [amount context mismatch] final dividend. Shareholders approved audited FY2026 financials and reappointed Adil Zainulbhai. The company emphasized growth in diabetes, respiratory, and emerging markets, with 40-50 new US/EU filings planned and Tirzepatide partnership advancing. R&D remains at 7% of revenue amid margin pressures.

📄 View Original Announcement (PDF)

📊 Stock Analysis — CIPLA ✨ Ask AI About This